Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.200
-0.160-0.63%
Volume:7.14M
Turnover:180.29M
Market Cap:21.97B
PE:73.36
High:25.640
Open:25.300
Low:24.940
Close:25.360
52wk High:34.800
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.70
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:2.30
PE(LYR):73.36
PS:4.69

Loading ...

Hutchmed H1 Earnings Rise, Revenue Falls

MT Newswires Live
·
Aug 07

Earnings Flash (HCM) Hutchmed Posts H1 Earnings $2.61 Per ADS

MT Newswires Live
·
Aug 07

HUTCHMED (China) H1 EPS $2.65 Up From $0.15 YoY, Sales $277.677M Down From $305.681M YoY

Benzinga
·
Aug 07

HUTCHMED (China) - Updates FY25 Guidance for Oncology/Immunology CONSOL Revenue to $270 Mln - $350 Mln

THOMSON REUTERS
·
Aug 07

HUTCHMED Reports 2025 Interim Results

THOMSON REUTERS
·
Aug 07

Corrected-HUTCHMED (China) H1 Revenue USD 277.7 Million (Corrects Amount)

THOMSON REUTERS
·
Aug 07

HUTCHMED (China) Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

BOCOM International: Innovative Drug Sector's Recovery Prospects Remain Attractive; Focus on Commercial Insurance Drug Catalog Launch

Stock News
·
Jul 16

HUTCHMED (China) Ltd. Schedules Board Meeting to Approve and Announce 2025 Interim Results

Reuters
·
Jul 03

HUTCHMED to Announce 2025 Half-Year Financial Results

GlobeNewswire
·
Jul 03

Hutchmed New Drug Application for Lung Cancer Combination Treatment Approved in China

MT Newswires Live
·
Jun 30

BUZZ-HUTCHMED hits 2-month high on drug application for kidney cancer treatment

Reuters
·
Jun 05

HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment

Reuters
·
Jun 05

BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab

Reuters
·
Jun 05

HK Movers | HK's Pharma Shares Soar. Hengrui Pharma Surges 29%; Asymchem up 7%; CSPC Pharma up 4%

Tiger Newspress
·
May 23

Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China

MT Newswires Live
·
Apr 22

Market Chatter: Hutchmed Looking Into Supply Chain Options for Blood Cancer Drug Amid US Tariffs

MT Newswires Live
·
Apr 15

Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment

MT Newswires Live
·
Mar 24

BRIEF-Hutchmed (China) Gets NMPA Conditional Approval For Tazverik® (Tazemetostat)

Reuters
·
Mar 21

Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

MT Newswires Live
·
Mar 21